pinflix yespornplease
Lydon, Nicholas

A Community of Rambunctious Scholars Celebrating People
Who Have Made Lifesaving Discoveries And Encouraging
Students and Politicians to Read 1000 Science Stories!

Nicholas Lydon

How fast can you count to this #?

We Need Your Help!

Do You Know This Scientist?

If you do, we welcome your input.  Please share your funny stories, brief anecdotes, quotes, and photos of the scientist - as well as your own inspirational opinions.  Personal accounts help bring a scientist alive and create an enduring historical picture.  You can be a part of this exciting history by providing your personal account! 

Please click here to learn more about how to contribute:
Participate as a Friend Scholar

Can You Write or Research?

Help us learn more about this great scientist.  You can be a credited Support Scholar by contributing your knowledge about this scientist and important discovery.  Entries can be as short as a single section and as easy as compiling quotes.  Click here to learn more about becoming a Support Scholar:
Participate as a Support Scholar

Would you like to adopt a scientist?

Endeavor to research all the sections of a scientist. Click here to learn how to be an Expert Scholar.
Participate as an Expert Scholar

Have Historically Significant Photographs?
Participate with Photos

Click here for all the ways you can participate:
Participate to


Has this scientist’s science impacted your life?
Click here to tell your story or to read others’ life changing anecdotes:
Post Your Own Testimonial

Nicholas Lydon
( 1957- )
Born in
Year of Discovery: 1996

Gleevec is Cause for Glee for Leukemia Patients

Cancer doctors witnessed the results with awe and amazement.  Their patients who teetered near death, previously without hope, were leaving the hospital, feeling well, full of new optimism, after being dosed with a new drug.  Gleevec is the “Magic Bullet” drug that attacks only the molecule which causes a form of leukemia (chronic myelogenous leukemia - CML), a ray of hope from teams of scientific minds led by Nicholas Lydon and Brian Druker. 

CML is one of the four main types of leukemia and begins with a change to a single stem cell.  The American Cancer Society predicts that in 2009 over 5000 people in the United States are expected to be diagnosed with CML.  Prior to 2001, CML was treated by chemotherapy, radiotherapy and bone marrow transplants.  Before the discovery and approval of Gleevac,  in May 2001, over 52% of patients diagnosed with CML died.  Today, over 90% of patients diagnosed with CML will survive beyond 5 years. Gleevac has switched CML from a fatal cancer to a manageable chronic condition.

Nicholas Lydon began his scientific journey at the University of Leeds in England where he received his bachelor’s degree in biochemistry.  He went on to complete his PhD in biochemistry at the University of Dundee in Scotland.  From 1982 to 1997 Lydon researched interferon, originally in Paris then in Basel, Switzerland. Lydon was recruited by Alex Matter to become the leader of the protein kinase inhibitor program at Ciba-Geigy Corporation, which would later become Novartis. A kinase is a type of enzyme that transfers phosphate groups in human cells. Kinases, of which more than 500 have been identified, transmit signals and control complex processes in cells.

In the late 1980s Lydon was introduced to oncologist Brian Druker.  At this time Druker was expanding his expertise in tyrosine kinases and Lydon was interested in developing tyrosine kinase inhibitors. Inhibitors are tiny molecules that fit themselves between two puzzle-like pieces of kinases, blocking the phosphate messages they are trying to send to each other. It turns out that in order for leukemia (CML) cells to grow they need a specific protein - BCR-ABL associated with tyrosine kinase. Stop it and maybe the cancer will stop. When Druker began looking for a tyrosine kinase inhibitor his very first call was to Lydon, who was anxious to begin testing on several inhibitors he thought might be promising.

“My vision was to come up with a small molecule drug that would specifically bind to this protein, and not to other proteins in the body that use the same mechanism,” explained Dr Lydon.  Druker screened Lydon’s compounds in human bone marrow cells, and one named STI571 stood out. STI571 targeted a section of the BCR/Able protein and it excelled at killing CML cells, leaving surrounding healthy cells unaffected.   “At that point I knew we had a potential drug,” says Druker.  Finally in 1996 the two scientists were successful in accomplishing development of the drug at Novartis. It was named Gleevec.

Over the next years they tested the drug. Usually with new drug trials, even promising drugs only improve a few more patients than other drugs, and then only marginally. But 53 of the 54 patients in the first drug trial with Gleevec markedly improved. Given the great results, they expanded the trial.  Knowing that it was working for patients in the chronic or stable phase of the disease, they offered it to patients in “blast crisis,” the name given to the late stage eruption of cancer.  That is when the most remarkable thing happened.  Patients who were at death’s door, were up and about and leaving the hospital within a week of their first dose. Less than 3 years after the first clinical study, the US Food and Drug Administration approved the drug. Now, the five year survival rate for CML patients is close to 90%. 

Since 2002 it has been working its magic on CML leukemia patients.

Another remarkable feature of the Gleevec story is that it is a new type of attack on cancer that has revolutionized drug development. Rather than trying to kill the cancer cells without killing other cells, which is the chemotherapy approach, Lydon and Druker targeted specific molecules inside the cancer cells. Already there are more than 500 drugs in development based on this new approach. According to Lydon, "The approval of Gleevec in 2001 represented a breakthrough in the treatment of cancer, yet we are really just starting to see the full promise of small molecule kinase inhibitors as targeted therapies for cancer and other important diseases."

In October of 2009 Lydon won the Lasker DeBakey Award, one of the highest honors in American science. Lydon was nominated for the Lasker Award by Professor Sir Philip Cohen, a leading biochemist from the University of Dundee, where Lydon received his PhD.  The Lasker award is shared with colleagues Brian Druker and Charles Sawyer. Sawyers’ work designed a second-generation inhibitor when resistance to Gleevec developed in some patients.  

Lydon currently leads Granite Biopharma LLC, a consulting company he formed in Jackson Hole, Wyoming.



Introduction by April Ingram


Table of Contents

Key Insight
Key Experiment or Research
Key Contributors
Quotes by the Scientist
Quotes About the Scientist
Fun Trivia About The Science
The Science Behind the Discovery
Personal Information
Science Discovery Timeline
Recommended Books About the Science
Books by the Scientist
Books About the Scientist
Major Academic Papers
Curriculum Vitae
Links to Science and Related Information on the Subject


Click the image to view Nicholas Lydon's Lasker Foundation interview

Image Flow Here

Key Insight

Key Experiments or Research

Key Contributors

The Team
Explore other scientists who furthered this lifesaving advance.
Lifesavers: Leukemia
Brian Druker
Developed Gleevec, a new-generation drug that targeted leukemia's mutated gene.
Charles Sawyers
Developed the next generation drug, Sprycel, for patients who resistant to Gleevec.

Quotes by the Scientist

Quotes About the Scientist


Fun Trivia About the Science

The Science Behind the Discovery

Personal Information

B.S., biochemistry
University of Leeds , England
Ph.D., biochemistry
Medical Sciences Institute , University of Dundee , Scotland
Ph.D., Biochemistry
Medical Sciences Institute , University of Dundee , Scotland

Scientific Discovery Timeline

Recommended Books About the Science

Books by the Scientist

Books About the Scientist



2009 Lasker DeBakey Clinical Medical Research Award

Lasker Foundation Press Release of Award

Lasker Foundation Award Article

Major Academic Papers Written by the Scientist

Curriculum Vitae

Links to Information on the Science

Journal of Clinical Investigation has an excellent in-depth article that also has personality anecdotes.